{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:44:36Z","timestamp":1772095476136,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>TAC chemotherapy is a standard adjuvant treatment for early\u2010stage breast cancer, with G\u2010CSF recommended for preventing febrile neutropenia (FN). This study investigates the optimal initiation timing for daily filgrastim to prevent FN in patients undergoing TAC chemotherapy, a subject not fully explored in existing guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixty breast cancer patients receiving adjuvant TAC chemotherapy were randomly assigned to start daily filgrastim either on Day 2 (Day 2 group, <jats:italic>n<\/jats:italic> = 30) or Day 5 (Day 5 group, <jats:italic>n<\/jats:italic> = 30). The primary outcome was the incidence of FN. Secondary outcomes included the duration of neutropenia treatment and the neutropenia profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients underwent 349 cycles of TAC chemotherapy (173 cycles in Day 2 group and 176 cycles in Day 5 group). The incidence of FN was significantly lower in the Day 2 group (6.4%, 11\/173) compared to the Day 5 group (22.2%, 39\/176, <jats:italic>p<\/jats:italic> &lt;\u00a00.0001). Additionally, the mean \u00b1 SD duration of filgrastim treatment was longer (8 \u00b1\u00a01 vs. 6 \u00b1\u00a01 days, <jats:italic>p<\/jats:italic> &lt;\u00a00.0001), and the duration of severe neutropenia was shorter (3 \u00b1\u00a01 vs. 4 \u00b1\u00a01 days, <jats:italic>p<\/jats:italic> = 0.001) in the Day 2 group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Initiating filgrastim on Day 2 of TAC chemotherapy significantly enhances its effectiveness in preventing FN compared to starting on Day 5. These findings support early intervention and sustained treatment to optimize toxicity management in adjuvant TAC chemotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.14165","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T05:15:51Z","timestamp":1743052551000},"page":"383-391","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Optimal Timing and Duration of Daily G\u2010CSF for the Primary Prevention of Febrile Neutropenia in Breast Cancer Patients Undergoing Adjuvant TAC Chemotherapy"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1413-2800","authenticated-orcid":false,"given":"Zisun","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Surgery Soonchunhyang University Bucheon Hospital Soonchunhyang University College of Medicine  Bucheon Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Mo","family":"Hur","sequence":"additional","affiliation":[{"name":"Department of Surgery Soonchunhyang University Bucheon Hospital Soonchunhyang University College of Medicine  Bucheon Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery Soonchunhyang University Cheonan Hospital Soonchunhyang University College of Medicine  Cheonan Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Wook","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Surgery Soonchunhyang University Cheonan Hospital Soonchunhyang University College of Medicine  Cheonan Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae Il","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Surgery Soonchunhyang University Cheonan Hospital Soonchunhyang University College of Medicine  Cheonan Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Yong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery Soonchunhyang University Cheonan Hospital Soonchunhyang University College of Medicine  Cheonan Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihyoun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery Soonchunhyang University Seoul Hospital Soonchunhyang University College of Medicine  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol Wan","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Surgery Soonchunhyang University Bucheon Hospital Soonchunhyang University College of Medicine  Bucheon Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"\u201cGLOBOCAN 2022: Global Cancer Statistics 2022 \u201dInternational Agency for Research on Cancer World Health Organization accessed April 26 2024.https:\/\/gco.iarc.fr\/today."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2023.26.e27"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043681"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910320"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70525-9"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.002"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.02.002"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-006-0119-4"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8823"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-6-200709180-00010"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01036-7"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-012-0830-2"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"e_1_2_9_15_1","unstructured":"\u201cClinical Practice Guidelines in Oncology: Hematopoietic Growth Factors Version 3 \u201dNational Comprehensive Cancer Network (NCCN) accessed April 26 2024.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw325"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl135"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg019"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0537-7"},{"key":"e_1_2_9_20_1","unstructured":"\u201cNeupogen\u00ae(Filgrastim) \u201d accessed February 15 2023.https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=103353."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm438"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3421-x"},{"key":"e_1_2_9_23_1","unstructured":"\u201cCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0 \u201dNational Institutes of Health National Cancer Institute published November 27 2017.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw098"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4074-8"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4522-5"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3854-x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-189"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0798-6"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-013-0442-x"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.14165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T09:44:14Z","timestamp":1754905454000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.14165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/ajco.14165"],"URL":"https:\/\/doi.org\/10.1111\/ajco.14165","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"2023-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}